The estimated Net Worth of Mikhail Eydelman is at least 3.69 百万$ dollars as of 3 September 2024. Mr Eydelman owns over 1,667 units of Vaxcyte stock worth over 3,689,580$ and over the last 3 years he sold PCVX stock worth over 0$.
Mr has made over 11 trades of the Vaxcyte stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 1,667 units of PCVX stock worth 35,690$ on 3 September 2024.
The largest trade he's ever made was exercising 20,000 units of Vaxcyte stock on 2 October 2023 worth over 428,200$. On average, Mr trades about 2,500 units every 19 days since 2022. As of 3 September 2024 he still owns at least 32,493 units of Vaxcyte stock.
You can see the complete history of Mr Eydelman stock trades at the bottom of the page.
Mikhail Eydelman J.D. is the Sr. VP, Gen. Counsel & Corp. Sec. at Vaxcyte.
Mr D is 43, he's been the Sr. VP、 Gen. Counsel & Corp. Sec. of Vaxcyte since . There are 10 older and no younger executives at Vaxcyte. The oldest executive at Vaxcyte, Inc. is Paul W. Sauer M.B.A., MBA, 60, who is the Sr. VP of Process Devel. & Manufacturing.
Mikhail's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS, CA, 94070.
Over the last 12 years, insiders at Vaxcyte have traded over 60,439,674$ worth of Vaxcyte stock and bought 1,293,000 units worth 20,688,000$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Capital Management, L.P.Ra ...、Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of 2,563,959$. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth 24,200$.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte executives and other stock owners filed with the SEC include: